Table 2.

Results from rounds 1 and 2 of the Delphi study of core domains for PMR. Numbers given are percentages of respondents selecting each outcome. Domains with > 70% agreement are highlighted in bold face; for each group (clinicians or patients), only domains with 20%–69% agreement in round 1 went forward to round 2. Bold face denotes that with > 70% agreement from either group in round 1 or round 2, the domain went forward into the combined round 3.

DomainRound 1 Clinicians, n = 60Round 1 Patients, n = 55Round 2 Clinicians, n = 55Round 2 Patients, n = 46
Stiffness severity56565374
Morning stiffness duration68368543
Muscle weakness125380
Sleep disturbance103557
Mood problems, low or “high”32037
Weight loss/gain25332748
Appetite loss/gain311
Balance problems27
Fevers/shivers/sweats/flu-like symptoms1215
Ability to do everyday activities51556574
Lack of mobility2535759
Dependence on stick, wheelchair, etc.02
Dependence on other people59
Ability to carry out usual roles (work, caring for others, etc.)20351637
Health-related quality of life50247639
Overall quality of life27511372
Change in appearance of face or body82241
Fluid retention/ankle swelling29
Bruising, poor healing, or other skin change52450
Doctor’s assessment of activity/severity of PMR59607183
Patient’s assessment of activity/severity of PMR764276
Blood tests864070
Abnormalities identified by physical examination by a doctor22720
Abnormalities identified by imaging tests36202933
Bone fragility271329
New or worsening diabetes mellitus145
High blood pressure1211
Cost of treatments used in the study311813
Overall costs to the healthcare provider36242211
Overall costs to society56405520
Any glucocorticoid-related adverse effect in judgment of doctor4663
Any glucocorticoid-related adverse effect in judgment of patient2380
  • “ — ” means the question was not asked in that round. PMR: polymyalgia rheumatica.